|
1
|
Bauer KR, Brown M, Cress RD, Parise CA and
Caggiano V: Descriptive analysis of estrogen receptor
(ER)-negative, progesterone receptor (PR)-negative, and
HER2-negative invasive breast cancer, the so-called triple-negative
phenotype: A population-based study from the California cancer
Registry. Cancer. 109:1721–1728. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ariazi EA, Ariazi JL, Cordera F and Jordan
VC: Estrogen receptors as therapeutic targets in breast cancer.
Curr Top Med Chem. 6:181–202. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Waqar SN and Morgensztern D: Precision
medicine in lung cancer: The battle continues. J Thorac Dis.
8:2991–2993. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Zhou C, Wu YL, Chen G, Feng J, Liu XQ,
Wang C, Zhang S, Wang J, Zhou S, Ren S, et al: Erlotinib versus
chemotherapy as first-line treatment for patients with advanced
EGFR mutation-positive non-small-cell lung cancer (OPTIMAL,
CTONG-0802): A multicentre, open-label, randomised, phase 3 study.
Lancet Oncol. 12:735–742. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Solomon BJ, Mok T, Kim DW, Wu YL, Nakagawa
K, Mekhail T, Felip E, Cappuzzo F, Paolini J, Usari T, et al:
PROFILE 1014 Investigators: First-line crizotinib versus
chemotherapy in ALK-positive lung cancer. N Engl J Med.
371:2167–2177. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Siegel RL, Miller KD and Jemal A: Cancer
Statistics, 2017. CA Cancer J Clin. 67:7–30. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Zhuo C, Li X, Zhuang H, Tian S, Cui H,
Jiang R, Liu C, Tao R and Lin X: Evaluating the efficacy and safety
of intravesical chemotherapies for non-muscle invasive bladder
cancer: A network meta-analysis. Oncotarget. 7:82567–82579.
2016.PubMed/NCBI
|
|
8
|
National Cancer Institute, . A Snapshot of
Bladder Cancer. https://www.cancer.gov/research/progress/snapshots/bladderNovember
5–2014
|
|
9
|
Guin S, Pollard C, Ru Y, Lew C Ritterson,
Duex JE, Dancik G, Owens C, Spencer A, Knight S and Holemon H: Role
in tumor growth of a glycogen debranching enzyme lost in glycogen
storage disease. J Natl Cancer Inst. 106:pii: dju0622014.
View Article : Google Scholar
|
|
10
|
Adeva-Andany MM, González-Lucán M,
Donapetry-García C, Fernández-Fernández C and Ameneiros-Rodríguez
E: Glycogen metabolism in humans. BBA Clin. 5:85–100. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Dagli A, Sentner CP and Weinstein DA:
Glycogen Storage Disease Type IIIGeneReviews®
[Internet]. Pagon RA, Adam MP, Ardinger HH, et al: University of
Washington; Seattle, WA: pp. 1993–2017
|
|
12
|
Lew C Ritterson, Guin S and Theodorescu D:
Targeting glycogen metabolism in bladder cancer. Nat Rev Urol.
12:383–391. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Hebbring SJ, Chai Y, Ji Y, Abo RP, Jenkins
GD, Fridley B, Zhang J, Eckloff BW, Wieben ED and Weinshilboum RM:
Serine hydroxymethyltransferase 1 and 2: Gene sequence variation
and functional genomic characterization. J Neurochem. 120:881–890.
2012.PubMed/NCBI
|
|
14
|
Jain M, Nilsson R, Sharma S, Madhusudhan
N, Kitami T, Souza AL, Kafri R, Kirschner MW, Clish CB and Mootha
VK: Metabolite profiling identifies a key role for glycine in rapid
cancer cell proliferation. Science. 336:1040–1044. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Guin S, Ru Y, Agarwal N, Lew CR, Owens C,
Comi GP and Theodorescu D: Loss of Glycogen Debranching Enzyme AGL
Drives Bladder Tumor Growth via Induction of Hyaluronic Acid
Synthesis. Clin Cancer Res. 22:1274–1283. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Karbownik MS and Nowak JZ: Hyaluronan:
Towards novel anti-cancer therapeutics. Pharmacol Rep.
65:1056–1074. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Tammi RH, Passi AG, Rilla K, Karousou E,
Vigetti D, Makkonen K and Tammi MI: Transcriptional and
post-translational regulation of hyaluronan synthesis. FEBS J.
278:1419–1428. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Wang A, de la Motte C, Lauer M and Hascall
V: Hyaluronan matrices in pathobiological processes. FEBS J.
278:1412–1418. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Lokeshwar VB, Mirza S and Jordan A:
Targeting hyaluronic acid family for cancer chemoprevention and
therapy. Adv Cancer Res. 123:35–65. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Nagy N, Kuipers HF, Frymoyer AR, Ishak HD,
Bollyky JB, Wight TN and Bollyky PL: 4-methylumbelliferone
treatment and hyaluronan inhibition as a therapeutic strategy in
inflammation, autoimmunity, and cancer. Front Immunol. 6:1232015.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Nikitovic D, Kouvidi K, Kavasi RM,
Berdiaki A and Tzanakakis GN: Hyaluronan/Hyaladherins - a Promising
Axis for Targeted Drug Delivery in Cancer. Curr Drug Deliv.
13:500–511. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Dicker KT, Gurski LA, Pradhan-Bhatt S,
Witt RL, Farach-Carson MC and Jia X: Hyaluronan: A simple
polysaccharide with diverse biological functions. Acta Biomater.
10:1558–1570. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Orian-Rousseau V: CD44 Acts as a Signaling
Platform Controlling Tumor Progression and Metastasis. Front
Immunol. 6:1542015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Misra S, Hascall VC, Markwald RR and
Ghatak S: Interactions between Hyaluronan and Its Receptors (CD44,
RHAMM) Regulate the Activities of Inflammation and Cancer. Front
Immunol. 6:2012015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Maxwell CA, McCarthy J and Turley E:
Cell-surface and mitotic-spindle RHAMM: Moonlighting or dual
oncogenic functions? J Cell Sci. 121:925–932. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Lokeshwar VB, Lopez LE, Munoz D, Chi A,
Shirodkar SP, Lokeshwar SD, Escudero DO, Dhir N and Altman N:
Antitumor activity of hyaluronic acid synthesis inhibitor
4-methylumbelliferone in prostate cancer cells. Cancer Res.
70:2613–2623. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Yates TJ, Lopez LE, Lokeshwar SD, Ortiz N,
Kallifatidis G, Jordan A, Hoye K, Altman N and Lokeshwar VB:
Dietary supplement 4-methylumbelliferone: an effective
chemopreventive and therapeutic agent for prostate cancer. J Natl
Cancer Inst. 107:djv0852015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Oldenburg D, Ru Y, Weinhaus B, Cash S,
Theodorescu D and Guin S: CD44 and RHAMM are essential for rapid
growth of bladder cancer driven by loss of Glycogen Debranching
Enzyme (AGL). BMC Cancer. 16:7132016. View Article : Google Scholar : PubMed/NCBI
|
